Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

Completed · Phase 2/Phase 3

Conditions studied: Hemophilia A

In brief

To assess efficacy and safety, including immunogenicity of BAX 855 administered as prophylaxis and as on-demand therapy in adult and adolescent (12-65 years) previously treated patients (PTPs) with severe hemophilia A To determine the pharmacokinetic (PK) parameters of BAX 855.

Key facts

Study ID
NCT01736475
Run by
Baxalta now part of Shire
People needed
159
Starts
2013-01-31
Expected to finish
2014-07-17
Last updated by the study team
2021-05-20

Who can join

Age: 12 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.